New antibody shows promise for blistering skin disease
NCT ID NCT04563923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested avdoralimab, an antibody that blocks a specific immune signal, added to standard steroid cream for bullous pemphigoid—a severe blistering skin condition mostly affecting older adults. Fifteen participants received the combination to see if it leads to complete remission faster than steroids alone. The study is small and early, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Avdoralimab (a monoclonal antibody) plus clobetasol propionate cream
- What this could lead to
- If it works, this could point toward a more targeted treatment for bullous pemphigoid that reduces reliance on steroids alone.
- What could go wrong
- This is a very small, early-phase trial with only 15 participants, so results may not apply broadly. The drug may not prove more effective than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHM, Hôpital Nord
Marseille, Bouches du rhône, 13000, France
-
APHM, Timone
Marseille, Bouche Du Rhône, 13005, France
-
CHU Montpellier, Dermatologie
Montpellier, Herault, 34005, France
-
CHU de Nice- Dermatologie
Nice, Alpes-Maritimes, 06200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study reveals bone risks from common skin treatment
- Scientists probe hidden clot risks in autoimmune skin disorders
- New study tests easier treatment for blistering skin disease
- One-Dose hope for blistering skin disease?
- New antibody treatment offers hope for rare blistering skin disease
- Researchers track blistering skin disease to pave way for better treatments